23.34 USD
↗ 0.97 (4.34%)AT CLOSE (03:59 PM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
22.78
↘ 0.56 (2.40%)
POST MARKET (AS OF 07:50 PM EDT)
Post Market
AS OF 07:50 PM EDT
22.78
↘ 0.56 (2.40%)
Market: CLOSED
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $23.34 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Oct 26, 2026.
Open?$22.50
High?$23.35
Low?$22.33
Prev. Close?$22.37
Volume?1.5M
Avg. Volume?2.1M
VWAP?$22.93
Rel. Volume?0.73x
Bid / Ask
Bid?$18.56 × 100
Ask?$26.52 × 100
Spread?$7.96
Midpoint?$22.54
Valuation & Ratios
Market Cap?2.5B
Shares Out?113.3M
Float?97.4M
Float %?86.0%
P/E Ratio?N/A
P/B Ratio?3.83
EPS?-$2.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
2.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?19
Momentum?75
Short Sent.?25
Piotroski F-Score?2/9Weak
Altman Z-Score?1.45Distress
Confidence?62%Moderate
Short InterestHigh
Short % of Float?18.48%High
Short Interest?18.0M
Days to Cover?8.0
Free Float97.4M
Avg Daily Volume2.2M
Settlement Date2026-10-15
Financial Health
Current Ratio?16.95Strong
Quick Ratio?16.95Strong
Cash Ratio?2.59Strong
Debt/Equity?0.54Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.83FAIR▾
Peers100
S&P46
P/S?35.63HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-6.7CHEAP▾
S&P97
EV/Sales?38.31HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-50.5%WEAK▾
S&P3
ROA?-30.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-335039000
Enterprise Value?$2.7B
Fundamentals ratios updated end of day